Royalty Pharma plc [RPRX] stock is trading at $39.39, up 1.36%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RPRX shares have gain 2.63% over the last week, with a monthly amount glided 1.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Royalty Pharma plc [NASDAQ: RPRX] stock has seen the most recent analyst activity on September 30, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $42. Previously, Morgan Stanley started tracking the stock with Overweight rating on May 16, 2025, and set its price target to $51. On June 03, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $28 on the stock. Scotiabank initiated its recommendation with a Sector Outperform and recommended $53 as its price target on May 13, 2022. Goldman started tracking with a Buy rating for this stock on April 27, 2022, and assigned it a price target of $56. In a note dated April 14, 2022, JP Morgan upgraded an Overweight rating on this stock but restated the target price of $50.
Royalty Pharma plc [RPRX] stock has fluctuated between $24.46 and $41.24 over the past year. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Royalty Pharma plc [NASDAQ: RPRX] shares were valued at $39.39 at the most recent close of the market. An investor can expect a potential return of 19.32% based on the average RPRX price forecast.
Analyzing the RPRX fundamentals
Royalty Pharma plc [NASDAQ:RPRX] reported sales of 2.35B for the trailing twelve months, which represents a growth of 7.90%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.8%, Pretax Profit Margin comes in at 0.72%, and Net Profit Margin reading is 0.44%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.15 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.85 points at the first support level, and at 38.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.72, and for the 2nd resistance point, it is at 40.04.
Ratios To Look Out For
For context, Royalty Pharma plc’s Current Ratio is 3.48. In addition, the Quick Ratio stands at 3.48 and the Cash Ratio stands at 0.52. Considering the valuation of this stock, the price to sales ratio is 9.68, the price to book ratio is 2.63 and price to earnings (TTM) ratio is 22.52.
Transactions by insiders
Recent insider trading involved Urist Marshall, EVP, Research & Investments, that happened on Dec 19 ’25 when 20000.0 shares were sold. EVP, Investments & CLO, Lloyd George W. completed a deal on Dec 17 ’25 to sell 79346.0 shares. Meanwhile, EVP, Investments & CLO Lloyd George W. sold 30654.0 shares on Dec 18 ’25.
